This document provides guidance on guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). It discusses initiation and titration of therapies including angiotensin receptor-neprilysin inhibitors, beta-blockers, sacubitril-valsartan, ivabradine, SGLT2 inhibitors, ACE inhibitors, ARBs, loop diuretics, and aldosterone antagonists. Key points include initiating therapies individually based on patient status, up-titrating doses every 2 weeks to maximize benefits, assessing for response using echocardiograms and biomarkers, and continuing GDMT even if ejection fraction improves to prevent heart failure events. Transcat
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Javed Butler, MD, MPH, MBA, discusses heart failure in this CME activity titled, "New Frontiers in Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?" For the full presentation, downloadable infographics, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2JG2v9l. CME credit will be available until May 29, 2020.
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Javed Butler, MD, MPH, MBA, discusses heart failure in this CME activity titled, "New Frontiers in Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?" For the full presentation, downloadable infographics, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2JG2v9l. CME credit will be available until May 29, 2020.
1. A Case report of Heart Failure
2. Discussion on Heart Failure
3. Role of Peptides in Heart Failure
4. Importance of 30 days in heart failure
5. Role of ENTRESTO in Stable Heart Failure patient (PARADIGM-HF study)(HFrEF)
6. Biomarkers in Heart Failure
7. Role of ARNI in Hospitalized Heart Failure patient (PIONEER-HF study)
8. Role of ARNI in HFpEF (PARAMOUNT Trial)
9. Safety and usefulness of ACEI/ARB/ARNI
10. Role of SGPL2 inhibitors in HF with/without DM
Beta Blockers in current cardiovascular practice Praveen Nagula
betablockers are the drug of choice for prevention of progression of heart failure with mortality benefit, after the evolution of neurohormonal regulation as pathogenesis of heart failure
1. A Case report of Heart Failure
2. Discussion on Heart Failure
3. Role of Peptides in Heart Failure
4. Importance of 30 days in heart failure
5. Role of ENTRESTO in Stable Heart Failure patient (PARADIGM-HF study)(HFrEF)
6. Biomarkers in Heart Failure
7. Role of ARNI in Hospitalized Heart Failure patient (PIONEER-HF study)
8. Role of ARNI in HFpEF (PARAMOUNT Trial)
9. Safety and usefulness of ACEI/ARB/ARNI
10. Role of SGPL2 inhibitors in HF with/without DM
Beta Blockers in current cardiovascular practice Praveen Nagula
betablockers are the drug of choice for prevention of progression of heart failure with mortality benefit, after the evolution of neurohormonal regulation as pathogenesis of heart failure
2009 Focused Update:
ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
J. Am. Coll. Cardiol. April 14, 2009; 53;1343-1382
Circulation. April 14, 2009;119;1977-2016
Medical Management of Heart Failure in the ClinicHenry Tran
This is a review focusing on medical therapies for Heart Failure. The intended audience is general internists and residents. There is a brief overview of Entresto and Corlanor as well.
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationDr Vivek Baliga
Dr Vivek Baliga of Baliga Diagnostics, Bangalore, discusses the common combination therapies used in the management of hypertension in clinical practice.
For each patient with AF, the two principal goals of therapy are symptom control and the prevention of thromboembolism.
Rate- and rhythm-control strategies improve symptoms, but neither has been conclusively shown to improve survival compared to the other.
First aid course focusing on management of burns, wounds of different types, disturbed conscious level and chemical intoxication whether by inhalation, ingestion or skin exposure.
Provides a simple organized way for ABG analysis with special emphasis on Acid-base balance interpretation & its crucial rule in clinical toxicology practice.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
2. Stages of heart failure
Stage A: At high risk for HF but without structural heart disease or symptoms of HF.
Stage B: Structural heart disease but without signs or symptoms of HF.
Stage C: Structural heart disease with prior or current symptoms of HF.
Stage D: Refractory HF requiring specialized interventions.
3. NYHA functional classification of HF
Class I: No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF.
Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in
symptoms of HF.
Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity
causes symptoms of HF.
Class IV: Unable to perform any physical activitywithout symptoms of HF, or symptoms of HF at rest.
4. Definitions
GDMT: treatment options supported for use by clinical practice guidelines.
HFrEF: Clinical diagnosis of HF and LVEF ≤ 40%.
Optimal GDMT: Treatment provided at either the target or the highest-tolerated dose for a given
patient.
Target dose: Doses targeted in clinical trials.
5. Current available GDMT for HFrEF
ARNIs, SGLT2 inhibitor, ACEIs, ARBs, beta-blockers, loop diuretics, aldosterone antagonists,
HYD/ISDN, and ivabradine.
With the exception of loop diuretics, all of these therapies have been shown in randomized
controlled trials to improve symptoms, reduce hospitalizations, and/or prolong survival.
Use of digoxin as a treatment for HFrEF lacks new data; most of its use in modern HFrEF
management focuses on its role as a rate control agent for atrial fibrillation in those with low
blood pressure.
6. Initiation of GDMT
There is NO difference to initiate therapy with either a beta blocker or ARNI/ACRI/ARB or both. Choice is
individualized to every patient.
Initiation of an ARNI/ACEI/ARB is often better tolerated when the patient is still congested “wet”, whereas
beta-blockers are better tolerated when the patient is less congested “dry” with an adequate resting heart
rate.
Beta-blockers should NOT be initiated in patients with decompensated signs or symptoms.
Regardless of the initiation sequence, both classes of agent should be up-titrated to the maximum tolerated
or target doses in a timely fashion (e.g., every 2 weeks).
7. Angiotensin Receptor-Neprilysin Inhibitor (ARNI)
Neprilysin inhibitor (Sacubitril) should NOT combined with an ACEI due to a higher risk of angioedema as angiotensin II is also a substrate for neprilysin.
PARADIGM HF Trial demonstrated an absolute 4.7% reduction in the primary outcome of CV death or HF hospitalization in patients treated with Entresto versus
enalapril with NNT of 21 patients over 27 months.
You may initiate ARNI without prior exposure to ACEI/ARB
There is NO existing predicate data to suggest an aldosterone antagonist is mandatory before ARNI therapy.
When making the transition from an ACEI to an ARNI, a 36-hour washout period should be strictly observed to avoid angioedema.
NO need for washout prior when transitioning from ARB to an ARNI.
The initiation of ARNI during an acute decompensated HF hospitalization is feasible after the patient has been hemodynamically stabilized making sure that the patient
is not volume depleted at the time of initiation to avoid hypotension.
In a stable noncongested patient, empiric lowering of loop diuretic dosage has been found to mitigate the hypotensive effects of Entresto.
Entresto remains indicated in chronic HFrEF and NYHA class IV symptoms if could be tolerated.
Entresto was not well studied in patients with GFR <30 or on dialysis.
8. Indications & Dose adjustments of Entresto
HFrEF (EF ≤40%)
NYHA class II–IV HF
Administered in conjunction with a background of GDMT for
HF in place of an ACEI or ARB.
10. Ivabradine (Corlanor)
A specific inhibitor of the If current involved in sinoatrial nodal activity and reduces the heart ate of patients in normal
sinus rhythm without lowering blood pressure.
Ivabradine is indicated only for patients mainly in sinus rhythm, not in those with persistent or chronic AF, those
experiencing 100% atrial pacing, or unstable patients.
History of paroxysmal AF is not a contraindication to ivabradine; however, patients should be in sinus rhythm at least 40%
of the time.
Recommended to reduce the risk of HF hospitalization in patients with EF ≤35% already receiving GDMT (including a beta-
blocker at the maximally tolerated dose), and who are in sinus rhythm with a heart rate >70 beats/min at rest.
Patients treated with ivabradine had greater rates of bradycardia and transient blurring of vision.
Titrate to heart rate 50–60 beats/min. Maximum dose 7.5 mg twice daily.
14. SGLT2 Inhibitors
Reduces hospitalization and mortality in patients with HFrEF regardless of the presence of diabetes.
Proposed mechanisms of benefit in HFrEF include osmotic diuresis and natriuresis, decrease in arterial
pressure and stiffness, shift to ketone-based myocardial metabolism, reduction of preload and afterload
blunting of cardiac stress/injury with less hypertrophy and fibrosis.
Meta-analysis of DAPA-HF and EMPEROR-Reduced suggested that the effects of empagliflozin and
dapagliflozin on hospitalization for HF were consistent and that these agents reduced all-cause and CV
death and improved renal outcomes in patients.
SGLT2 inhibitors have been associated with mild worsening of renal function during the first year of use.
20. Hydralazine/ISDN: Dosing & Titration
Consider increasing the dose of hydralazine and/or ISDN every 2 weeks until the
maximally tolerated or target dose is achieved.
Monitor BP after imitation and during titration.
22. Initiation and Titration of GDMT
After a diagnosis of HF is made, adjustment of therapies should occur every 2 weeks, and some patients
may tolerate more rapid titration of GDMT.
Clinicians should aim to achieve optimal GDMT within 3 to 6 months (if tolerated) of an initial diagnosis
of HF.
GDMT should continue to be up-titrated to achieve maximally tolerated or targeted doses of these
therapies.
During follow-up, frequent reassessment of the clinical status of the patient, blood pressure, and kidney
function (and electrolytes) should be performed.
Reassessment of ventricular function should occur 3 to 6 months after target (or maximally tolerated)
doses of GDMT are achieved to determine the need for device therapies such as ICD and CRT.
26. When to order a repeat Echocardiogram?
Once optimal doses of GDMT have been achieved for 3 to 6 months, repeat imaging can be useful in
making decisions regarding device therapy (ICD, CRT, or transcatheter mitral valve repair) or referral
for advanced therapies (LVAD or transplant).
In some patients, it may be reasonable to wait longer for such decisions if there is an expectation that
LV remodeling might further progress.
Repeat imaging may also be considered at the time of important changes in clinical status.
Routine surveillance echocardiograms (e.g., annually) in the absence of change in clinical status or
some other signal of risk are unwarranted.
27. When to repeat Natriuretic peptides?
Current guidelines give a Class I recommendation to measure BNP or NT-proBNP to support a clinical diagnosis of HF, assess
disease severity, or establish prognosis.
Higher concentrations of BNP or NT-proBNP in an ambulatory patient with HFrEF indicate high risk.
Patients whose natriuretic peptide concentrations do not fall with GDMT “nonresponders” have a worse prognosis and more
deleterious LV remodeling as shown in GUIDE-IT and PROVE-HF trials.
Measurement of BNP or NT-proBNP is useful to monitor risk, assist in decision-making regarding the ordering of imaging studies
to evaluate LV remodeling, and to provide helpful objective data regarding decision making for referral to advanced HF therapies.
In the setting of worsening symptoms, the reassessment of BNP or NT-proBNP may be informative.
Severe renal dysfunction may interfere with the interpretation of natriuretic peptide concentrations.
28. Effect of Entresto on natriuretic peptides
Due to neprilysin inhibition, concentrations of BNP sometimes modestly rise in patients treated
with Entresto and tend not to rapidly return to baseline despite chronic therapy.
In contrast, NT-proBNP concentrations typically decrease much more consistently than do BNP
concentrations, as NT-proBNP is not a substrate for neprilysin
Caution is advised when attempting to interpret BNP values in the context of ARNI treatment, and
NT-proBNP measurement may be preferable in this setting. However, during treatment, either
biomarker predicts the risk of major adverse outcomes in patients treated with Entresto.
29. Should we continue GDMT after improvement in EF?
The recent TRED-HF (Withdrawal of Pharmacological Treatment for Heart Failure in
Patients with Recovered Dilated Cardiomyopathy) study examined this question,
finding that nearly 50% of subjects withdrawn from GDMT had an HF event within
6 months. Therefore, in the absence of a defined, reversible cause for HFrEF (e.g.,
tachycardia-mediated cardiomyopathy), current GDMT should be continued.
30. Severe MR and the use of Transcatheter MV repair
Surgical treatment is recommended in cases of severe primary chronic MR resulting in HFrEF.
Initial steps should incorporate optimization of GDMT and participation in team management decisions before the
use of percutaneous transcatheter repair.
The MITRA-FR and COAPT trials reported divergent results. Whereas no benefit from percutaneous clipping of the
mitral valve was observed in MITRA-FR, the COAPT study investigators reported that, in a population with
maximally-tolerated GDMT and device therapy, there was a reduction in HF hospitalization and mortality in
symptomatic HF patients with grade 3 to 4+ MR.
Although percutaneous mitral valve repair is of benefit in patients with optimized GDMT and persistent symptoms
with severe MR, it is essential that GDMT is optimized before referral for the procedure to ensure the greatest
likelihood that patients will receive the combined benefits of optimal GDMT together with edge-to-edge repair.
31. Assessment of filling pressure
Pulmonary artery catheterization results may also help select candidates for
advanced therapies, including transplantation or mechanical circulatory support.
CHAMPION trial examined the role of CardioMEMS (wireless implantable
pulmonary artery pressure monitor) to guide changes in GDMT and diuretic doses. It
resulted in 28% relative reduction in HF (reduced and preserved EF) hospitalization.
In well-selected patients with recurrent congestion, this highly specialized
monitoring strategy may guide therapeutic decision-making.
34. Patients in whom new therapies may NOT be Indicated
In a patient whose life expectancy is short (<1 year) due to
other comorbidities, some therapies (such as implantable
devices) may not be appropriate.
Similarly, in patients with NYHA class IV and Stage D HF being
considered for advanced therapies (i.e., transplant or LVAD),
home inotropes, hospice, or initiation of new drug therapies
may not be appropriate.
35. Barriers to titration of GDMT
Patients seen in clinical practice may differ substantially from those enrolled in trials.
Abnormal renal function and/or hyperkalemia are common barriers to initiation and titration of GDMT.
Newer potassium binders (patiromer and sodium zirconium cyclosilicate) are now approved by the FDA and may be considered;
however, more data are needed regarding use of such agents in patients with HFrEF.
In those with severe renal impairment (eGFR <30 mL/ min/1.73 m2), the starting dose of sacubitril/valsartan should be reduced to 24/26
mg twice daily.
Aldosterone antagonists are contraindicated in patients with severe renal impairment (eGFR <30 mL/ min/1.73 m2, or creatinine >2.5
mg/dL in men or creatinine >2 mg/dL in women) or with potassium >5.0 mEq/L.
Renal function and potassium should be assessed within 1 to 2 weeks after initiation or dose increase of an ARNI/ACEI/ARB.
Renal function and potassium after initiation and titration of aldosterone antagonists should be assessed within 2 to 3 days and again at
7 days. Later, should occur at least monthly for the first 3 months and every 3 months thereafter.
Socioeconomic barriers to care may undermine the ability to achieve GDMT. For example, the cost of therapies poses a substantial
barrier to care.
37. References
• Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, Ladden-Stirling AB, Miller M,
Orringer CE, Stone NJ. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk
Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology
Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-993. doi:
10.1016/j.jacc.2021.06.011. Epub 2021 Jul 28. PMID: 34332805.
• Yancy CW, Januzzi JL Jr., Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of
heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a
report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll
Cardiol. 2018;71:201–30.
• Januzzi JL, Butler J, Fombu E, et al. Rationale and methods of the prospective study of biomarkers, symptom
improvement, and ventricular remodeling during sacubitril/valsartan therapy for heart failure (PROVE-HF).
Am Heart J. 2018;199:130–6.
• Myhre PL, Vaduganathan M, Claggett B, et al. Btype natriuretic peptide during treatment with sacubitril/
valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73:1264–72.
• Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors:
JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422–34.